December 6, 2016 11:28 AM EST
Bioregnum
Pharma
Opinion

Is the US bio­phar­ma in­dus­try head­ed for a turn­ing point in 2017?

Three months ago, Brent Saun­ders fired a shot across the bow of the USS Big Phar­ma, pledg­ing to lim­it Al­ler­gan’s an­nu­al price in­crease on …

Endpoints Premium

This article is available only to Premium subscribers

Upgrade to Premium for unlimited access and Premium exclusives.

UPGRADE
TRENDING NOW

Trump an­nounces picks for FDA, CDC; No­var­tis seeks bolt-on deals, rais­es guid­ance; RFK Jr., Elon Musk may find ...

For CDC, Trump picks Dave Wel­don, a for­mer con­gress­man who pushed for vac­cine in­jury claims

Trump names Johns Hop­kins re­searcher Mar­ty Makary to lead the FDA; al­so names CDC, Sur­geon Gen­er­al picks

FDA ap­proves Bridge­Bio's heart dis­ease drug, set­ting up com­pe­ti­tion with Pfiz­er, Al­ny­lam

Sanofi in­tro­duces new 340B pay­ment mod­el — re­port

sponsored

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

A service from the Financial Times